Drug Profile
Research programme: anticancer therapeutics - Affichem
Alternative Names: AF 122; AF300; AFF 354; DDA; Dendrogenin ALatest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator AFFICHEM
- Developer Affichem
- Class Small molecules; Sterols
- Mechanism of Action Cell differentiation stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Cancer; Colorectal cancer; Leukaemia; Malignant melanoma
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for Breast cancer in France (unspecified route)
- 27 Dec 2022 Discontinued - Preclinical for Cancer in France (unspecified route)
- 27 Dec 2022 Discontinued - Preclinical for Colorectal cancer in France (unspecified route)